Učitavanje...
Biomarkers in individualized management of chimeric antigen receptor T cell therapy
The development of chimeric antigen receptor (CAR) T cell immunotherapy has achieved promising results, both in clinical studies and in commercial products for patients with hematologic malignancies. Despite high remission rates of CAR-T cell therapy in previously untreatable, refractory and/or rela...
Spremljeno u:
| Izdano u: | Biomark Res |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7216329/ https://ncbi.nlm.nih.gov/pubmed/32426136 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00190-8 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|